As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls.  Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading ->
Italy has become the first nation to require pharmaceutical companies to disclose secret data about any public subsidies it may have received for the development of a new drug, during negotiations over drug pricing and reimbursement with national regulatory authorities, according to a decree published Friday in the nation’s official gazette. The decree, following on […] Continue reading ->
About 1.7 billion people, or 22% of the world’s population, has at least one underlying health condition that puts them at increased risk of becoming seriously ill with COVID-19, according to a new modelling study published in Lancet Global Health.   Based on the new assessment, about 4% of the world’s population, in total, is at […] Continue reading ->
As the 73rd World Health Assembly approaches, the European Union-sponsored draft resolution on the COVID-19 response is gathering steam and storm as it rolls closer to the planned opening of the Assembly on 18 May – with far less clarity about how it might actually hit the shores of the public debate.  The resolution aims […] Continue reading ->
Up to 190 000 Africans could die of COVID-19 within the first year of the pandemic if containment measures fail. And up to 44 million Africans, or 26% of the African population, could be infected by the virus, according to a new modelling study  by the World Health Organization Regional Office for Africa. A proactive […] Continue reading ->